Advisory Board November 13, 2023

Amid high demand and short supply of the weight-loss drug semaglutide, some patients have turned to counterfeit versions. Following several reports of patient harm associated with counterfeit semaglutide, FDA has opened an investigation into the cases and said that it is “vigilant in protecting the U.S. drug supply from these threats.”

High demand leads to counterfeit semaglutide

Currently, the United States is facing a shortage of weight-loss drugs, including Novo Nordisk’s semaglutide, even as manufacturers make efforts to boost production.

In July, there were reports of some companies offering “generic” or...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma, Pharma / Biotech
FDA issues flu vaccine recommendations: 5 respiratory updates
5 Digital Health Areas To Be Impacted By The FDA Layoffs
FDA Approves First Biosimilar to Omalizumab
Trump's Nominees to Run FDA, NIH Get Greenlighted by Senate Committee
FDA Debuts a New Communications and Compliance Tool for Device Data Integrity Concerns

Share This Article